Sirtris Pharmaceuticals Completes Exclusive License to Harvard University's SIRT3-Based Intellectual Property

Published: Sep 16, 2008

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris, a GSK Company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that it has completed an agreement with Harvard University to exclusively license two patent applications covering SIRT3-based methods of treatments and assays.

Back to news